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ABSTRACT 
Natural Killer (NK) cells are a type of blood immune cells that are capable of lyse 
the infected or transformed cells without prior sensitization. Due to a small fraction 
of NK cells within human bodies, and the fact that the cells are not able to expand 
to lyse the target cells, cells were isolated from human blood, and were expanded. 
NK cells expanded without feeder cells showed only a small number of fold 
expansion. However, when the NK cells were co-cultivated with artificial Antigen 
Presenting Cells (aAPCs), NK cells showed a much greater number of fold 
expansion. Especially, NK cells co-cultured with K562 cells with membrane bound 
IL-21 (K562.mbIL21) showed about 10,000-fold expansion for 14 days cultivation. 
Continuous cultivation of NK cells with the K562.mbIL21 showed more than 100 
billion-fold expansion for 30 days before it shows senescence. By employing a 
multivariate analysis technique, phenotypic changes during the activation and 
expansion of NK cells were captured. In addition, various kinetic parameters during 
the cultivation were identified to provide preliminary data for future research. It was 
found that NK cells could expand with dead aAPCs and their debris, showing a 
possibility of expanding NK cells without feeder cells since the K562 cells are 
cancerous, thus, they need to be completely removed for clinical use in promoting 
NK cells in the field of adoptive immunotherapy.  
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1 INTRODUCTION 
1.1 CELL THERAPY 
Cell therapy is a method of treating diseases using living whole cells by 
administering the cells to patients suffering from many genetic disorders and some 
acquired ones. It aims to target various cellular diseases by certain cell populations 
or carrying cells that can be used for therapeutic use. In addition to cell therapy, 
gene therapy has brought tremendous influence in the development of genetic 
modifications on cells for treatment purposes. Two fields of gene and cell therapy 
have created such a synergy for unmet medical needs. 
Cells used for the cell therapy can be originated from either a patient (autologous) 
or a donor (allogeneic). Blood infusions are considered the first generation of cell 
therapy and are now everyday practices. Bone marrow transplantation is another 
type of cell therapy started in early days to treat disease like cancer and 
immunodeficiency. Nowadays, cell therapy is expanding to utilize more types of 
cells including stem cell, T cell and Natural Killer cell. 
1.2 APPLICATION OF CELL THERAPY (CAR-T AND NK) 
Among a few recent advancements in medicine, cancer immunotherapy has 
achieved the most advances in terms of the amount of research that has been 
done, and the number of ongoing clinical trials (J. F. Miller & Sadelain, 2015). T-
cell immunotherapy has shown tremendous success treating certain types of 
cancers, such as lymphoma, leukemia, and melanoma. Autologous T cells are 
obtained from patient's blood, and are engineered so that the T cells will be 
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redirected to specifically target cancer cells in the patient’s body. Then, the 
engineered T cells are infused back to the patient (Couzin, 2002). By doing the 
engineering of the T cells using gene editing techniques, it will enhance the 
capability to kill the target cell more efficiently. One of the technique involves 
expressing receptors like chimeric antigen receptors (CARs). The CARs are 
composed of an antigen recognition domain from monoclonal antibody and a 
domain that is responsible for T cell signaling and co-stimulation. Those CAR T 
cells have shown efficacy to treat B-cell malignancy by targeting the CD19 cell 
surface antigen (Levine, Miskin, Wonnacott, & Keir, 2017). The first CAR-T cell 
therapy was approved in 2017 by Novartis. More and more CAR-T therapies 
targeting different types of cancers are under clinical trials. 
Natural Killer (NK) cells play important roles in human by initiating responses to 
infections, such as influenza, cytomegalovirus (CMV), herpes simplex virus (HSV), 
and respiratory syncytial virus. The potential of NK cell due to its antiviral, anti-
graft-versus-host disease, and anti-cancer functionality, it is expected that NK cells 
can be used to treat certain indications, including sarcomas, myeloma, 
carcinomas, lymphomas, and leukemias (Denman et al., 2012). 
There are a few challenges that NK cell therapy have to overcome. It is important 
to understand NK cell biology fully so that NK cells can be manufactured with 
highest cytotoxicity possible for use in clinical applications (Koepsell, Miller, & 
McKenna, 2013). Once the variables that contribute to the NK cell activation, the 
cells need to be expanded with persistence for commercial manufacturing. 
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1.3 NEED OF SCALABILITY AND SCALE UP 
Most CAR-T therapies that are either approved or in clinical trial employ 
autologous T cells, meaning T cells from the patient himself/herself. Because of 
high efficacy of CAR-T cells derived from autologous T cells, there is no need for 
a large number of T cells during the cell engineering. Despite of the fact that 
autologous CAR-T therapy has shown superior results compared to allogeneic 
CAR-T therapy, there are allogeneic CAR-T therapies under clinical trials. One 
limitation for the allogeneic therapy is coming from difficulty to expand the number 
of cells ex vivo (Vera et al., 2010; Yang, Jacoby, & Fry, 2015). While autologous 
therapy is for only one patient, allogenic therapies need to provide sufficient 
number of cells for multiple patients.  
Such needs for rapid expansion are also of utmost concern for NK cell therapy. 
Compared to T cells that dominate within the lymphocytes, NK cells comprise of 
only 5-15% of human lymphocytes that limited number of NK cells can be obtained 
from a single donor or patient. In case of a single clinical trial for 100 patients, each 
patient needs at least a single infusion of 2 x 107 NK cells/kg (Meyer-Monard et al., 
2009). Assume each patient weighs 100 kg, NK cells need to be expanded to 2 x 
1011 NK cells to provide a sufficient number of cells for a single trial. In case 
multiple infusions are needed throughout the treatment, the total number of NK cell 
needs to be multiplied by the number of infusion. 
Moreover, ex vivo scale up of NK cell expansion is not only needed for a large 
number of cells for therapy, but also for priming NK cells that were resistant to lyse 
the target cells. Generally, NK cells are not showing good functionality within 
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human body, prior to priming, because their activating receptors are 
downregulated. Ex vivo expansion with certain combination of cytokines will greatly 
enhance the cytotoxicity against tumors. It is now clear that there needs a method 
to expand NK cells sufficiently to meet the needs in both clinical and commercial 
scale, and also enhance the function against immunosuppression (Granzin et al., 
2017). 
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2 BACKGROUND 
2.1 BACKGROUND: WHAT IS A NK CELL? 
Natural Killer (NK) cells belong to a distinct subset of large granular lymphocytes 
within the human immune system. Because of its innate nature rather than 
adoptive, the name itself had been derived from its cytolytic function that mediates 
spontaneous and nonspecific lysis of target cells without any priming. One major 
difference between T cell and NK cell is how NK cells recognize the target cell. 
Thanks to Major Histocompatibility Complex (MHC) molecules expressed on the 
surface of cells that are either transformed or virus infected, NK cells can recognize 
the cells that lacks the MHC molecules for lysis (Ljunggren & Karre, 1990). 
There are about two billion NK cells flowing around in a human body. From a 
traditional point of view, NK cell can be defined as a cell phenotype expressing 
CD56, a 140-kDa isoform of cell adhesion molecule (NCAM) found on NK cells, 
and lacks CD3, a T cell marker. Therefore, by using flow cytometry, a gate can be 
applied to include NK cells while excluding T cells. While CD56+CD3- phenotype 
still defines a NK cell nowadays, Vivier has suggested using NKp46, a natural 
cytotoxicity receptor (NCR) family that belongs to activating receptor, as a defining 
phenotype of NK cell (Walzer, Jaeger, Chaix, & Vivier, 2007)  
NK cells secrete cytokines and chemokines that affect the host’s immune response 
and have a capability to lyse certain infected and transformed cells by perforin and 
granzyme. NK cells also induce the death of target cells by inducing death receptor 
related pathways, such as Fas and TRAIL (Smyth et al., 2005). There are two 
distinguished subsets of NK cells. CD56brightCD16- population shows mostly 
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immune modulatory function by secreting interferon (IFN)-g. CD56dimCD16+ 
population shows direct cytotoxic functionality by secreting perforin and granzyme 
(Vivier, Tomasello, Baratin, Walzer, & Ugolini, 2008). 
 
2.2 CELL THERAPY PROCESS (CULTIVATION, FREEZE, THAW) 
There are different culture systems that can culture NK cells ex vivo. The size of 
the system typically depends on the purpose of the system as well as the number 
of cells needed. 
In research laboratories where testing various conditions is the purpose of the 
culture, cell culture plates and T flasks are used for pre-clinical experiments. 
However, due to the small volume of each condition, cell culture plates and T flasks 
are difficult to produce enough number of cells for clinical purposes. For expansion 
purposes, it takes as much as 51 T flasks to produce NK cells that can be used for 
just a single dose (Parkhurst, Riley, Dudley, & Rosenberg, 2011). As the number 
of flasks increases, more manual manipulations are needed to culture cells for 
exchanging media and harvesting the cells for passaging. It will eventually 
increase a risk of contamination during the process that it is not an idealistic 
method for NK cell expansion for clinical purposes. 
Disposable bags can be used for NK cell expansion. Because the volume of a bag 
can be much larger than its T flask counterpart, much larger number of cells can 
be obtained. While cells settle down at the bottom of the bag, media in the bag can 
be changed using a tubing at the top of the bag making the overall process easier. 
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By using disposable bags, all tubings can be welded without breaking the sterile 
boundary so that the risk of contamination is lower than flask culture. There are 
multiple reports describing reduction of expansion rate once cells are transferred 
from a small flask to a larger disposable bag (Siegler et al., 2010; Sutlu et al., 
2010). 
In order to avoid frequent media exchange during the culture, a cell culture flask 
with gas permeable membrane was developed, named G-Rex. The G-Rex looks 
like a regular media bottle, but the membrane at the bottom for exchanging carbon 
dioxide and transfer oxygen from external environment. If cells are cultured in a T 
flask with high volume of cell culture media, cells will not be able to receive enough 
oxygen from outside, and will eventually die due to hypoxia. The membrane is 
designed to supply oxygen for cells settled at the bottom. Now with G-Rex, it is 
usually filled with media to the neck of the body, and is kept under culture condition 
without changing the media for more than 10 days without changing media. G-Rex 
was able to yield higher cell number compared to cell culture bags (Lapteva et al., 
2012). Although there is less risk of contamination, the risk from manual handling 
still exists. The size of the G-Rex is also a concern that the surface area at the 
bottom is still not enough to produce a large number of cells. 
Automated systems can be used to culture NK cells without human intervention. It 
increases accuracy of liquid handling and decreases the risk of contamination. The 
initial capital cost for the automated system is larger than the cost of manual cell 
handling. However, due to lower cost of human manpower, the cost of running the 
system in a long term will be lower. First generation of automated system is using 
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a bioreactor. Both stainless steel and disposable bioreactors showed their 
capability culturing NK cells for expansion. The bioreactors are capable of 
controlling temperature, agitation, dissolved oxygen level, and supplying nutrient 
feed if necessary. However, setting up the reactor and transferring cells in and out 
still need human intervention, which may pose a risk of contamination because NK 
cells need to be isolated from blood. In addition, additional steps, such as washing 
the cells after cultivation and concentrate the cell density may be necessary after 
cell expansion that are difficult to be performed inside the bioreactor. 
In an effort to develop an automated system that can handle multiple unit 
operations in a single machine, CliniMACS Cell Separation system provides a 
closed system handling steps including isolation from blood, washing, labeling with 
antibody followed by separation, expansion, volume reduction for higher cell 
concentration, and final buffer formulation prior to cryopreservation (Apel et al., 
2013). 
 
2.3 NK CELL CULTURE: AUTOLOGOUS FEEDER CELLS 
Cytokines play important roles during maturation and expansion of NK cells. 
However, the degree of expansion caused by adding cytokines to the culture is not 
high enough that it is difficult to meet the demand of NK cells for clinical and 
commercial use. By adding autologous feeder cells from the patient, it triggers 
better expansion compared to culture proliferating NK cells alone. In Peripheral 
Blood Mononuclear Cells, there are T cells, B cells, NK cell and monocytes. T cells 
have a distinct marker CD3, B cells have CD19, and monocytes have CD14. For 
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instance, CD19+ monocytes enhance NK cell expansion by direct cell to cell 
contact, and by secreting molecules that triggers NK cell expansion (J. S. Miller, 
Oelkers, Verfaillie, & McGlave, 1992; Pierson, Miller, Verfaillie, McGlave, & Hu, 
1994).  
While autologous feeder cells are cultured with NK cells, a combination of 
cytokines and antibodies, such as IL-2, IL-15, OKT-3 (Anti-CD3 Antibody), are 
added to promote a better growth. OKT-3 is known to activate T cells within the 
autologous cell population, and the activated T cells stimulate NK cells to expand. 
A number of reports indicated that autologous feeder cells yield better expansion 
of NK cells while the number of T cells in the culture also expand. At the end of the 
culture, only 30-60% population was NK cells, and the rest was mostly T cells 
(Barkholt et al., 2009; Carlens et al., 2001; Geller et al., 2011; Sutlu et al., 2010). 
In the effort to avoid growing population of T cells, autologous feeder cells can be 
irradiated. This will result in very small population of T cells at the end of expansion. 
The benefit of irradiation is not only preventing unwanted cells growing, but also 
inducing stress-induced surface markers, such as UL Binding Protein. Activating 
receptor NKG2D recognizes UL Binding Protein on the surface of the feeder cells. 
By recognizing the stress-induced markers, NK cells are better activated (Ahn et 
al., 2013). 
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2.4 NK CELL CULTURE: ALLOGENEIC FEEDER CELLS 
One advantage that allogenic feeder cells carry is an ease of having off the shelf 
stock of the feeder cells. Because the feeder cells are not coming from the patient 
directly, Peripheral Blood Mononuclear Cells (PBMCs) from other donors can be 
used as well as established cell lines can be developed. In the previous section, 
autologous PBMCs were culture with NK cells to increase the proliferative capacity. 
When allogeneic PBMCs were cultured with NK cells, it yielded around 300-fold 
expansion compared to 169-fold expansion when autologous PBMCs were utilized 
(Kim et al., 2013). 
While PBMCs give NK cells signals for proliferation either in direct or indirect 
manner, cell lines such as K562 and Epstein-Barr virus infected cells give much 
higher proliferative signals compared to PBMCs. The advantage of stimulation with 
genetically modified K562 is not just higher cell numbers, but also higher 
cytotoxicity compared to unstimulated NK cells. 
K562 is a leukemia cell line that is well known to be a target cell for lysis by NK 
cells. During the course of lysis of K562, NK cells become activated by 
upregulating surface receptors. K562 cell lines had been genetically modified to 
express certain molecules that typically do not exist on the surface of NK cells. The 
molecules are also known to stimulate and expand T cells. 
There are different combinations of molecules that were transduced on K562, 
including CD137L, MICA, 4-1BB Ligand, IL-15, IL-21. Because gamma chain 
cytokines are also known to promote NK cell expansion, IL-15 and IL-21 were 
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mixed with media in soluble form, but they were able to be expressed on K562 to 
stimulate NK cells at a higher level. 
Fujisaki transduced K562 cell lines with constructs encoding membrane bound 
form of IL-15, CD8α, and 4-1BB ligand. Because K562 expands faster than NK 
cells, K562 needs to be irradiated prior to co-culture. During 7 day co-culture, the 
number of NK cells expanded from 5.1 to 86.6 fold (median 21.6 fold) compared 
to the number of NK cell on Day 0 (Fujisaki et al., 2009). All cells undergo 
senescence after a prolonged culture period. NK cells showed slower growth rate 
when they were cultured with K562 with membrane bound IL-15. 
Denman showed that NK cells co-cultured with K562 membrane bound IL-21 does 
not show senescence after 60 days of culture. The genetically modified K562 were 
produced by retroviral transduction with CD64 (FcγRI), CD86 (B7-2), CD137L (4-
1BB), and truncated CD19 with membrane bound IL-21 using Sleeping Beauty 
transposon. He showed on average 47,967-fold expansion after 21 days of co-
culture with genetically modified K562. Denmen stated that the reason why 
membrane bound IL-21 performed superior compared to membrane bound IL-15 
was due to the length of telomere of NK cells with K562 membrane bound IL-21 
cells was maintained 10% longer than the length of telomere before stimulation on 
Day 0 while the length of telomere of NK cell cultured with K562 membrane bound 
IL-15 showed 10% shorter compared to Day 0 (Denman et al., 2012). 
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2.5 EFFECT OF CYTOKINES ON NK CELL ACTIVATION AND EXPANSION (IL-
2, IL-15, IL-21) 
There is an array of surface receptors on the surface of cells. Cytokines bind to 
those receptors, and regulate survival, activation, expansion of the cells. 
Interleukin-2 (IL-2) binds to IL-2R (Letter ‘R’ denotes receptor), and activates NK 
cells. It was originally identified as a T cell growth factor. However, it also 
stimulates NK cells by upregulation of natural cytotoxicity receptors (NCRs) and 
NKG2D. Also, a proportion of KIR+ population increased over KIR- population 
(Huenecke et al., 2010). After activation of NK cells by IL-2, they showed higher 
cytotoxicity against K562. 
While IL-2 is better known for its activation characteristics of NK cells, IL-15 has 
received its popularity for expansion of NK cells. IL-15 also belongs to gamma 
chain cytokines. Similar to IL-2, it was first identified a T cell growth factor. Later, 
it was also found that the in vitro effect of IL-15 is comparable to IL-2 because the 
signaling by both IL-2 and IL-15 occurs at the same location called IL-2/15 Rβ and 
γc subunits. However, in vivo effect of IL-2 and IL-15 are different (Bamford et al., 
1994; Carson et al., 1994; Grabstein et al., 1994). Besides its effect of activating 
of NK cells, IL-15 causes functional exhaustion of the cells as it alters in vivo 
activity of the NK cells (Felices et al., 2016). Therefore, proper dose and duration 
of cultivating NK cells with IL-15 should be carefully considered to avoid the 
exhaustion effect. 
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IL-21 is another member of gamma chain cytokine that is known to enhance 
expansion of NK cells. It is produced by CD4+ T cells and has effects on different 
types of cells. When NK cells are cultured with media containing IL-21, effector 
function of NK cell is enhanced showing higher cytotoxicity and ADCC responses 
(McMichael et al., 2017). 
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3 METHODS 
3.1 ISOLATION OF PERIPHERAL BLOOD MONONUCLEAR CELLS FROM 
BLOOD 
Concentrated blood samples are obtained from Memorial Blood Centers in 
Minneapolis, MN using a blood processing system such as TRIMA ACCEL blood 
component centrifuge manufactured by Terumo BCT, Inc. The volume of 
concentrated blood in the blood cell collection device is approximately 10 mL. 
Dilute the concentrated blood with 50 mL of Phosphate Buffered Saline (PBS, 
Corning 21-040-CV). Use a syringe to purge leftover blood in the blood cell 
collection device. In a 50 mL falcon tube (Falcon 352098), aliquot 20 mL of Ficoll-
Paque PREMIUM density gradient media (GE Healthcare 17-5442-03), then gently 
fill up the tube with 30 mL of the diluted blood. The tubes can be centrifuged at 400 
g for 30 minutes with no brake. From the top of the tube, there will be a layer of 
plasma, mononuclear cells, Ficoll-Paque media, and a combination of 
granulocytes and erythrocytes. 
Remove upper half of plasma. Then, collect the lower half of plasma and a thin 
layer of mononuclear cells. Centrifugate the collected mononuclear cells at 400 g 
for 5 minutes. Remove the supernatant and add 20 mL of PBS with 2% Human AB 
Serum and 2% EDTA. Count the number of cells accordingly. 
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3.2 ISOLATION OF NK CELLS FROM PBMC 
Wash the PBMC twice using PBS with 2% Human AB Serum and 2% EDTA. Adjust 
the cell concentration to 1 x 108 cells/mL, and transfer the cells into a 14 mL 
polystyrene round-bottom tube (Corning 352051). Add Selection Cocktail to the 
tube at 100 µL/mL of the sample from each of EasySep Human CD3 Positive 
Selection Kit II (STEMCELL Technologies 17851) and EasySep Human CD19 
Positive Selection Kit II (STEMCELL Technologies 17854). Mix and incubate at 
room temperature for 3 minutes. Vortex RapidSpheres magnetic beads for 30 
seconds before adding to the tube. Add magnetic beads to the tube at 100 µL/mL 
of the sample in the tube. Mix and incubate at room temperature for 3 minutes. If 
the volume of sample is less than 2 mL, top up with PBS with 2% Human AB Serum 
and 2% EDTA to 3 mL level of the tube. If the volume of sample is more than 2 
mL, top to with PBS with 2% Human AB Serum and 2% EDTA to 10 mL level of 
the tube. Place the tube into The Big and Easy magnet (STEMCELL Technologies 
18001) at room temperature for 3 minutes. Pick up the magnet, and in one 
continuous motion invert the magnet and tube, pouring off the supernatant. 
Remove the tube from the magnet; this tube contains the isolated cells. Repeat 
the magnetic isolation twice more for better purity of the sample. Count the number 
of cells at the end. The sample includes NK cells and monocytes. 
EasySep Human NK Cell Enrichment Kit (STEMCELL Technologies 19055) can 
be used for a pure population of NK cells without monocytes from PBMC following 
the same step described above. 
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3.3 CULTIVATION OF NK CELLS 
500 mL of NK cell culture media contains 300 mL of Dulbecco’s Modified Eagle 
Medium (DMEM) with 25mM HEPES, 4.5 g/L glucose, and L-glutamine, without 
sodium pyruvate (Corning 10-027), 150 mL of Ham’s F-12 medium (Corning 10-
080), 50 mL Heat-inactivated Human AB Serum (Valley Biomedical HP 1022HI), 5 
mL Penicillin and Streptomycin (Gibco 15140), 20 uM 2-Mercaptoethanol (Sigma 
M7522), 50 uM Ethanolamine (Sigma E0135), 10 ug/mL Ascorbic Acid (Sigma 
A4544), and 1.6 ng/mL Sodium Selenite (Sigma S5261). 
 
Genetically modified K562 cells were obtained from Fate Therapeutics. Upon 
collection of either CD3, CD19 depleted or CD56 enriched NK cells, 8 x 106 cells 
were placed in a T-75 flask (Corning 353136) with 40 mL of media. 1.6 x 107 
genetically modified K562 cells were added to the T-75 flask. Half-volume media 
changes are performed on day 3 and 5 without diluting the cells. On day 7, NK 
cells are diluted to 5 x 106 cells, and genetically modified K562 cells are added at 
a 1:1 ratio for re-stimulation. From day 7 onwards, full-volume media changes were 
performed every 2 or 3 days while diluting the NK cells to 1 x 107 cells. Re-
stimulation by genetically modified K562 cells were performed every 7 days. 
Cell counts were performed using Tripan-Blue Dye Exclusion method. Countess II 
Automated Cell Counter (Thermo Fisher Scientific) was used to determine the 
number of cells in a single slide containing 5 µL of Trypan-Blue solution, and 5 µL 
of cell culture sample. 
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3.4 SURFACE ANTIBODY STAINING FOR FLOW CYTOMETRY 
5 x 105 cells were obtained from the culture. Wash the cells with PBS before 
starting the procedure. Place cells into a 5 mL polystyrene round-bottom tube 
(Falcon 352052).  
Following antibodies were subsequently added to stain the cells. 
Table 1: List of Antibodies for Flow Cytometry 
Target Color Manufacturer Cat. No. 
CD366 Brilliant Violet 421 Biolegend 345008 
CD11a FITC Biolegend 301206 
CD96 PE/Dazzle 594 Biolegend 338414 
CD85j (ILT2) Per/CP Cy 5.5 Biolegend 333714 
TIGIT APC R&D Systems FAB7898A 
CD45RA Brilliant Violet 421 Biolegend 304130 
CD16 FITC Biolegend 302006 
CD2 Brilliant Violet 510 Biolegend 300218 
CD44 Brilliant Violet 510 BD 563029 
CD164 FITC Biolegend 324806 
CD52 PE/Dazzle 594 Biolegend 316014 
CD56 PE/Cy7 Biolegend 92189 
CD16 Brilliant Violet 421 Biolegend 302038 
CD3 Brilliant Violet 785 Biolegend 93380 
IFN-g Brilliant Violet 650 Biolegend 93705 
NKG2D Brilliant Violet 510 Biolegend 320816 
CD117 Brilliant Violet 711 Biolegend 313230 
KIR2DL1 (CD158) FITC Biolegend 339504 
KIR3DL1 (CD158j) FITC Biolegend 312706 
KIR2DL2 (CD158b) FITC Biolegend 312604 
CD319 PE/Dazzle 594 Biolegend 331812 
CD62L Per/Cp Cy 5.5 Biolegend 304824 
CD107a Per/Cp Cy 5.5 Biolegend 92580 
NKG2A (CD159a) PE Beckman Coulter IM3291U 
CD81 Per/Cp Cy 5.5 Biolegend 349508 
DNAM-1 (CD226) Per/Cp Cy 5.5 Biolegend 338314 
CD44 Brilliant Violet 510 BD 563029 
18 
 
Because the number of colors that can fit into a single panel is limited, antibodies 
were grouped into three different panels. 
Table 2: List of Markers Used for Three Flow Cytometry Panels 
Color Panel 1 Panel 2 Panel 3 
PE-Cy7 CD56 CD56 CD56 
APC-Cy7 Livedead Livedead Livedead 
BV605 CD57 CD57 CD57 
BV786 CD3 CD3 CD3 
FITC 3KIRs LFA-1 CD164 
PE NKp30 NKG2C NKG2A 
PE-CF594 CD319 CD96 CD52 
PerCP-Cy 5.5 CD62L ILT2 CD81 
APC N/A TIGIT CD45RO 
Alexa Flour 700 2B4 N/A N/A 
BV421 CD16 TIM-3 CD45RA 
BV510 NKG2D CD2 CD44 
BV711 CD117 N/A N/A 
 
The shaded region in the table represents that are in common among all three 
panels. Those were used to gate NK cell population from the sample, and 
determine the level of maturity by CD57. 
In case of complex antibody staining that consists of multiple colors, the antibodies 
need to be mixed with BD Brilliant Stain Buffer (BD 563794) to prevent antibodies 
aggregate each other. The tube is incubated at 4 °C for 30 minutes. 
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3.5 SPADE ANALYSIS 
SPADE (Spanning-tree Progression Analysis of Density-normalized Events) is a 
method to identify specific subset of cell populations using data files obtained from 
multidimensional flow cytometry analysis. Flow cytometry data consists of the 
expression intensity of every single cell processed through the cytometer. SPADE 
clusters all cells in the data into a defined number of ‘nodes’ and visualize the 
nodes into a tree like structure. Due to the nature of cytometry, SPADE can be 
used for both flow cytometry and mass cytometry. 
3.5.1 Establishment of SPADE Analysis Methodology 
One of the biggest advantages of the SPADE is the ability to visualize multi-
dimensional data into a single plane. Because there are different phenotypes 
present in every single sample, it is important to combine the data into one single 
file so that the combined dataset can present all the phenotypes possible 
throughout the co-cultivation. 
NK cells cultivated from five donors were used to collect the data. A publicly 
available tool, Cytobank (Kotecha, Krutzik, & Irish, 2010), was used to analyze the 
data using SPADE. Cytobank provides a tool to concatenate multiple FCS files into 
one single FCS file. All individual FCS files that are concatenated must have the 
same markers and channels aligned to avoid errors during the concatenation. 
(Figure 1) 
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Figure 1: Cytobank File Concatenation Tool 
 
When the data was visualized using histograms, all five donors showed similar 
expression although the degree of activation by co-cultivation varied depending on 
the donor. 
Each node represents a group of cells showing similar phenotype expression 
intensity. Defining the correct number of nodes will bring the best results. By setting 
the number lower, the shape of the tree will be simplified. However, it will also 
compromise the chance to detect a rare or subtle population. This is so called 
"underclustering". On the other hand, setting the number of the nodes higher than 
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needed, so called “overclustering”, will be clustering the data at a high definition, 
but will require more time to analyze and form a bubble that contains multiple 
nodes showing similar characteristics. In order to define the right number of nodes 
for the dataset, a number of SPADE analysis were tested that gave the smallest 
node that contained less than 0.1% of the total population. When 150 nodes 
SPADE analysis was created, the smallest node contained 0.08% of the total 
population, which satisfied the criteria of less than 0.1%. 
Nodes that had similar phenotypes were manually clustered based on pre-defined 
criteria, named ‘bubble’. By using this method, proportion of certain phenotypes of 
interest can be easily identified and visualized among multiple donor or patient. 
Once all the bubbles were formed, median values of each node were calculated. 
Cytobank used the median values to show the intensity of each node. The median 
value right after clustering was presented in a linear scale. Then, the linear median 
values were transformed into a new scale called ‘arcsinh’. 
The flow cytometer equipment used for this experiment (BD LSR II) used Log10 
scale to visualize the data in two-dimension, and also biexponential scaling to 
avoid pitfall of failure to display data near zero. In cytobank, it supports log-like 
scale called ‘arcsinh’ to allow for configuration of the linear region around zero 
through adjustment of the cofactor. 
By looking at the histograms, and overlaying them to check the difference between 
the donor, initial conclusion was the donor variation exists, but it should not affect 
the analysis too much. In order to verify the effect of donor variation, a dataset 
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contained all five donors, and another dataset contained only one donor flow 
cytometry data files were compared.  
For the analysis of all five donors concatenated, the dataset contained all files 
listed in Table 3, plus one concatenated file. For the analysis of one donor, the 
dataset contained files belong to only one donor cultivated using one type of feeder 
cells. 
Table 3: List of Samples Tested 
Donor ID Feeder Type Sampling Day 
SLR833 Native K562 0 
7 
14 
K562.mbIL10 
 
0 
7 
14 
K562.mbIL15 0 
7 
14 
K562.mbIL21 0 
7 
14 
SLR842 Native K562 0 
7 
14 
K562.mbIL10 0 
7 
14 
K562.mbIL15 0 
7 
14 
K562.mbIL21 0 
7 
14 
SLR843 Native K562 0 
7 
14 
K562.mbIL10 0 
7 
14 
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Donor ID Feeder Type Sampling Day 
K562.mbIL15 0 
7 
14 
K562.mbIL21 0 
7 
14 
SLR856 Native K562 0 
7 
14 
K562.mbIL10 
 
0 
7 
14 
K562.mbIL15 0 
7 
14 
K562.mbIL21 0 
7 
14  
SLR859 Native K562 0 
7 
14 
K562.mbIL10 
 
0 
7 
14 
K562.mbIL15 0 
7 
14 
K562.mbIL21 0 
7 
14 
NOTE: All Day 0 samples are tested before starting the co-
culture. This means there will be only one Day 0 sample file 
available for each donor even though the table lists as a 
separate file. 
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3.5.2 Comparison between 5-donor and 1-donor Concatenated 
Dataset 
In order to make sure five-donor data concatenation did not have much effect on 
the analysis due to donor to donor variation, proportion of pre-defined phenotypes 
were compared between the two datasets to show the comparability. Among the 
three panels, Panel 1 was chosen, and also three donors among five to compare 
the proportion of certain phenotypes. 
There were four phenotypes defined by looking at the most dominant phenotype 
shown on each sampling day. From Panel 1, there were 9 markers available (3KIR, 
NKp30, CD319, CD62L, 2B4, CD16, NKG2D, CD117 and CD57) while excluding 
common markers across the three panel to gate the NK cells. Only 4 out of 9 
markers showed clear separation of positive and negative phenotype when they 
were visualized in histogram (Figure 2). 
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d)
 
Figure 2: Flow Cytometry Intensity Histogram for 3KIRs, NKp30, CD16, NKG2D 
(a) Flow Cytometry Intensity Histogram for 3KIRs. Day 0, 7, 14 (Left to Right) 
(b) Flow Cytometry Intensity Histogram for NKp30. Day 0, 7, 14 (Left to Right) 
(a) Flow Cytometry Intensity Histogram for CD16. Day 0, 7, 14 (Left to Right) 
(a) Flow Cytometry Intensity Histogram for NKG2D. Day 0, 7, 14 (Left to Right) 
 
Other markers did not show clear separation between positive and negative 
phenotype. Therefore, all nine markers were clustered by SPADE, but only 4 of 
which had shown clear separation were annotated. 
For the four markers annotated, values that separates phenotypes were recorded 
in linear scale. Because cytobank used an arcsinh transformation, the linear values 
obtained from histogram visualization were transformed in excel by 
‘=ASINH(value/cofactor)’ command. Note that the value of cofactor was obtained 
from scale setting of each panel. 
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Figure 3: SPADE Figure from Donor SLR833, Day 0. Generated from Five Donor 
Concatented Dataset 
Red bubbles indicate 3KIRs-NKp30-CD16+NKG2D-, which were dominant on Day 0. 
Green bubbles indicate 3KIRs+NKp30-CD16+NKG2D+, and blue bubbles indicate 
3KIRs-NKp30+CD16+NKG2D+, which were dominant on Day 7. Purple bubbles 
indicate 3KIRs+NKp30+CD16+NKG2D+, which were partially dominant on Day 14, and 
also the most idealistic phenotype. 
 
Based on the gating values defined, four different pre-defined phenotypes that are 
dominant on Day 0, 7, and 14 were grouped into bubbles. 
After defining the bubbles of each phenotype from a SPADE figure that contains 
all five-donor data, the exact same bubbles were used to measure proportion of 
each phenotype present on each donor and each day. Figure 3, Figure 4, Figure 
5 show only one donor, and how the proportion changes over time. 
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Figure 4: SPADE Figure from Donor SLR833, Day 7. Generated from Five Donor 
Concatenated Dataset 
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Figure 5: SPADE Figure from Donor SLR833, Day 14. Generated from Five Donor 
Concatenated Dataset 
 
By calculating the number of cells captured within a bubble, proportions of each 
phenotype in the five-donor concatenated dataset were calculated. In order to 
compare the characteristics of each bubble, the average values of each bubble 
were also calculated. 
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Table 4: Proportion of pre-defined phenotypes from five donor concatenated dataset 
Proportion 
(%) 
Day 0 Day 7 Day 14 
Donor / 
Phenotype A B C D A B C D A B C D 
SLR 833 70.08 0.01 0.39 0.19 6.53 5.80 16.41 19.36 4.19 1.84 5.53 31.95 
SLR 842 72.45 0.22 0.74 0.54 4.88 3.26 41.77 23.30 12.05 1.51 8.41 18.20 
SLR 856 51.91 0.08 0.43 0.24 35.92 3.39 3.38 4.74 2.55 0.53 18.30 25.74 
A represents 3KIRs-NKp30-CD16+NKG2D-. B represents 3KIRs+NKp30-CD16+NKG2D+. C represents 3KIRs-
NKp30+CD16+NKG2D+. D represents 3KIRs+NKp30-CD16+NKG2D+. 
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Table 5: Average intensity of each bubble from five-donor concatenated dataset 
Average 
Intensity 
3KIRs NKp30 CD16 NKG2D CD319 CD62L 2B4 CD57 CD117 
A 1.31 1.31 2.27 1.65 0.37 0.78 1.00 1.64 0.28 
B 4.65 1.52 2.63 3.53 0.90 0.18 1.41 0.90 0.56 
C 1.30 3.28 2.29 3.73 1.06 0.42 1.40 0.33 0.59 
D 4.67 3.22 2.55 3.67 1.08 0.56 1.56 1.43 0.54 
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After determining the characteristics of five donor concatenated dataset, the same 
procedure was repeated for one donor dataset. The same procedure was repeated 
for the three donors to identify changes in proportion among different donors. 
Figure 6, Figure 7, Figure 8will show only the SPADE figures for donor SLR 833, 
but the Table 6 and Table 7include all calculations to determine the comparability. 
After all the characteristics from individual donor data were calculated, data 
between five-donor and one-donor datasets were compared. It was concluded that 
proportions of phenotypes measured from both dataset showed similarity to negate 
the variation between the two datasets.  
 
Figure 6: SPADE Figure from Donor SLR833, Day 0. Generated from One Donor 
Concatenated Dataset 
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Figure 7: SPADE Figure from Donor SLR833, Day 7. Generated from One Donor 
Concatenated Dataset 
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Figure 8: SPADE Figure from Donor SLR833, Day 14. Generated from One Donor 
Concatenated Dataset 
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Table 6: Proportion of pre-defined phenotypes from one donor concatenated dataset 
Proportion 
(%) 
Day 0 Day 7 Day 14 
Donor / 
Phenotype 
A B C D A B C D A B C D 
SLR 833 67.09 0.05 0.29 0.10 4.01 16.75 28.07 13.27 3.98 3.33 7.13 31.03 
SLR 842 76.73 0.03 0.20 0.18 4.10 1.09 49.55 27.54 19.26 0.87 8.77 21.08 
SLR 856 67.24 0.12 0.13 0.07 42.69 2.31 1.38 2.45 4.74 0.26 19.09 25.77 
 
A represents 3KIRs-NKp30-CD16+NKG2D-. B represents 3KIRs+NKp30-CD16+NKG2D+. 
C represents 3KIRs-NKp30+CD16+NKG2D+. D represents 3KIRs+NKp30-CD16+NKG2D+ 
Each bubble consists of multiple nodes that has different median values. Weighted median was calculated for each bubble 
to determine the characteristics of each bubble. 
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Table 7: Average intensity of each bubble from one donor concatenated dataset. 
Donor Average 
Intensity 
3KIRs NKp30 CD16 NKG2D CD319 CD62L 2B4 CD57 CD117 
SLR 
833 
A 2.35 1.38 2.97 0.86 0.25 0.62 0.83 4.23 0.17 
B 4.55 1.32 2.34 3.39 1.03 0.42 1.43 2.91 0.45 
C 1.27 2.83 2.48 3.60 1.03 0.57 1.43 0.40 1.01 
D 4.56 3.27 2.90 3.66 1.13 0.42 1.72 1.74 0.68 
SLR 
842 
A 1.58 1.61 2.80 1.25 0.40 0.99 0.99 2.13 0.24 
B 4.12 1.20 2.42 3.39 0.72 0.34 1.44 1.65 0.09 
C 1.31 3.18 2.93 4.16 1.21 0.62 1.48 0.55 0.76 
D 4.45 3.28 2.92 3.88 1.13 0.40 1.64 0.72 0.76 
SLR 
856 
A 1.13 1.44 1.91 1.54 0.35 1.23 1.00 1.19 0.23 
B 4.72 1.11 2.41 3.58 1.01 0.91 1.68 0.57 1.19 
C 0.86 3.71 2.20 3.71 1.09 0.41 1.52 0.00 0.73 
D 4.70 3.59 2.42 3.62 1.00 0.67 1.64 0.18 0.64 
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Figure 9: Comparison between five-donor concatenated and one-donor concatenated for each pre-defined phenotype across 
3 donors.
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3.6 GLUCOSE CONSUMPTION MEASUREMENT 
Glucose consumption by NK cells was measured by taking supernatant samples 
from the culture every 2-3 days during the cultivation. In order to quantify the 
amount of glucose in the supernatant, Infinity Glucose Hexokinase Liquid Stable 
Reagent (Thermo Scientific TR15421) was used. In a 96 well plate, 2 µL of sample 
was mixed with 300 µL of the reagent. The mixture was kept in 37 °C for 30 minutes 
for incubation, and was measured for absorbance at 340 nm using Tecan Infinite 
200 PRO plate reader. The actual amount of glucose in the solution was calculated 
by fitting the absorbance value into a pre-determined slope that measured known 
concentration of glucose solution. All measurements were done in triplicate to 
ensure consistency of the measurements. 
 
3.7 OXYGEN CONSUMPTION MEASUREMENT 
Oxygen consumption by NK cells was measured using NeoFox Phase Fluorometer 
to quantify the amount of dissolved oxygen in the cell culture media. In order to 
measure the level of dissolved oxygen changing over time, the probe was 
calibrated per the instructions of the fluorometer. During the cultivation, certain 
number of cell was sampled, and was centrifuged to lower the volume so that cell 
density can be increased. Centrifuged cells were placed into a 1.8 mL HPLC vial 
(Agilent Technologies), and the media was filled up to 1 mL. In order to avoid gas 
transfer between ambient air and the liquid, 200 µL of paraffin oil (EMD Millipore) 
was place on top of the solution. 
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After placing a blue cap with septa (Agilent Technologies), the septa was 
punctured with the measurement probe, and placed into a waterbath that was set 
to 37.0 °C. 
Initial and final concentration of dissolved oxygen was measured, and also the 
slope was plotted to ensure the oxygen level dropped in a linear fashion. 
 
  
40 
 
4 RESULTS 
4.1 LIMITATION OF NK CELL CULTIVATION WITHOUT FEEDER CELLS 
NK cells isolated from three donors and enriched by magnetic bead isolation as 
described in Materials and Methods were inoculated into 24 well plate at 1 x 106 
cells/mL. The medium was supplemented with a gamma chain cytokine IL-15 at 
50 IU/mL. Complete media replenishment was performed on Day 7. All donors 
showed only limited growth over 14 days. The final cell concentration was 2.35, 
2.27, 1.57 x 106 cells/mL respectively.  
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Figure 10: Cell Concentration of NK Cells with IL-15, and without Feeder Cells 
Each symbol represents different donors. 
 
4.2 FEEDER CELLS WITH MEMBRANE BOUND CYTOKINES SUPPORTS RAPID 
EXPANSION 
NK cells cultured without any feeder cells resulted only a few folds expansion over 
14 days as described in 4.1. Next, the NK cells, at 0.2 x 106 cell/mL initially, were 
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co-cultured with four different types of K562 cells that had been irradiated at 10,000 
cGy as artificial Antigen Presenting Cells (aAPCs). The four types of K562 cells 
were: Native K562, K562 with membrane bound IL-15 (K562.mbIL15), membrane 
bound IL-10 (K562.mbIL10), and membrane bound IL-21 (K562.mbIL21). The 
growth curves are shown in Figure 11. The numbers of fold expansion are shown 
in Figure 12. 
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Figure 11: Cell Concentration During the K562 aAPC Co-Cultivation 
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Figure 12: NK Cell Fold Expansion during the Co-Cultivation with K562 aAPCs 
 
It was questionable how long can K562.mbIL21 promote such a rapid expansion. 
Beyond 14 days cultivation, one donor was selected, and the cultivation was 
continued beyond 14 days. After 33 days, the growth rate started slowing down, 
and was not able to reach previously achieved growth rate after re-stimulation. On 
Day 35, the number of fold expansion reached 100 billion-fold. 
 
Figure 13: NK Cell Expansion for Extended Period 
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4.3 CO-CULTURE WITH FEEDER CELLS REGULATE SURFACE RECEPTORS  
There are a number of receptors expressed on the surface of NK cell to determine 
the functionality of the cell. Among them, Killer Ig-like Receptors (KIRs) are 
inhibitory receptors that balance the activation signals from activating receptors, 
and also related to acquisition of the core function of NK cell (Cichocki et al; 2010). 
KIRs are composed of KIR2DL1 (CD158), KIR3DL1 (CD158j), KIR2DL2 
(CD158b). Three types of antibodies that can capture all three different KIR were 
used to capture the level of KIR expression on NK cells. Over 14 days of culture 
period, the level of KIR expression were upregulated regardless of the type of 
molecules expressed on the surface of K562 aAPC as well as Native K562. 
 
 
Figure 14: 3KIRs Expression on NK cells expanded on K562 aAPCs 
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NKp30 is one of the activating receptors that recognize specific ligands on the 
target cells. While the expression of NKp30 was less than 20% of all NK cell 
population on Day 0, more than half of NK cell populations activated with all types 
of K562 aAPCs and Native K562 expressed NKp30.  
 
 
Figure 15: NKp30 Expression on NK cells expanded on K562 aAPCs 
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CD16 is another type of activating receptors that is also known as Fc receptor. It 
allows the cell to recognize the target cells coated with antibody, and thus enables 
antibody-dependent cell cytotoxicity (ADCC, Vivier et al; 2004). While all types of 
K562 were able to main high level of CD16 expression, K562 aAPCs were able to 
support even higher level of CD16 expression on NK cells after co-culture. 
 
 
Figure 16: CD16 Expression on NK cells expanded on K562 aAPCs 
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Even though NK cells rely on the expression of MHC Class I to identify the target, 
NKG2D is expressed on the surface of NK cells as a homodimer, and recognize 
non-classical MHC molecules such as MICA and MICB, and also non-MHC 
molecules such as ULBP1-6. Those non-classical and non-MHC molecules are 
expressed in response to either viral infection or tumor formation on the cells.  
(Foley et al; 2014). The expression of NKG2D was close to none on Day 0, but 
showed highest expression on Day 7. Among four different types of K562, the one 
bearing cytokine IL-21 was able to upregulate NKG2D the most compared to other 
types of K562. 
 
 
Figure 17: NKG2D Expression on NK cells expanded on K562 aAPCs 
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LFA-1 (CD11a) is an adhesion molecule that when NK cells encounter the target 
cells, adhesion through β2 integrin LFA-1 happens so that a process of lysis can 
begin. Recent research has discovered that LFA-1 is not only responsible for 
adhesion with the target, but also transmit activation signals during the early stage 
of lysis (Barber et al; 2004). Cultivation with K562 upregulated the level of LFA-1 
expression on NK cells. By Day 14, NK cells co-cultivated with K562.mbIL21 
showed higher expression of LFA-1 compared to others. 
 
 
Figure 18: LFA-1 Expression on NK cells expanded on K562 aAPCs 
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NKG2C (CD94) is an activating receptor that belongs to C-type lectin superfamily 
that binds to HLA-E (Lanier et al; 1998) It is also reported that NKG2C is expressed 
on expanding NK cell subsets caused by human cytomegalovirus (HCMV) or other 
viruses (Schlums and Cichocki et al; 2015). It was  rare to find a donor with 
high level of NKG2C expression on Day 0. Most donors in this experiment showed 
rather low levels of NKG2C initially. After co-cultivation, most NK cells showed 
higher levels of NKG2C compared to Day 0. 
 
 
Figure 19: NKG2C Expression on NK cells expanded on K562 aAPCs 
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Not much is known about CD96. It is a member of Ig family that shares the ligand 
CD155 with CD226 and TIGIT. CD155 is the main ligand for CD96 (Chan et al; 
2014). NK cells cultured with K562.mbIL21 showed higher expression of CD96 in 
general, but the expression faded away after Day 7. 
 
 
Figure 20: CD96 Expression on NK cells expanded on K562 aAPCs 
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CD2 is another type of adhesion molecule on the surface of NK cells. Day 0 NK 
cells showed moderate level of CD2 expression, and the level of expression was 
upregulated during the co-cultivation. Both Day 7 and 14 NK cells were able to 
retain high level of CD2 expression. 
 
 
Figure 21: CD2 Expression on NK cells expanded on K562 aAPCs 
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NKG2A, also known as CD159a, is an inhibitory receptor that forms a heterodimer 
with CD94. The heterodimer binds to HLA-E, which is a type of non-classical MHC 
class I. NK cells showed relatively low level of NKG2A expression on Day 0. After 
the co-culture, NKG2A was upregulated on Day 7. By Day 14, it showed higher 
level of NKG2A, but slightly lower compared to Day 7. 
 
 
Figure 22: NKG2A Expression on NK cells expanded on K562 aAPCs 
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CD81 was identified as a protein that inhibits lymphocyte proliferation. In addition, 
it was identified to be a marker of hepatitis C virus (HCV) infection of hepatocytes. 
Once HCV binds to CD81 on NK cells, it will inhibit killing and cytokine production 
by NK cells (Crotta et al; 2002). Initially shown at a low level of expression of CD81, 
more than half of the population expressed CD81 on Day 7, and the expression 
slightly diminished on Day 14. 
 
 
Figure 23: CD81 Expression on NK cells expanded on K562 aAPCs 
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CD45 is a big family of multiple isoforms that are coming from a single gene. 
CD45RA is known to be expressed on naïve T cells and resting NK cells. As cells 
become activated, CD45RA losses its expression, and another isoform, named 
CD45RO, is expressed. CD45RO is expressed on activated and memory T cell 
and activated NK cells. As shown in the figure, CD45RA is expressed at a high 
level on Day 0, and losses its expression over the course of co-cultivation. 
CD45RO is almost not captured on Day 0, but becomes highly expressed on Day 
7 and 14. 
 
 
Figure 24: CD45RA, CD45RO Expression on NK cells expanded on K562 aAPCs 
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CD44 is responsible for lympho-hemopoiesis, adhesion to high endothelial venules 
or the extracellular matrix, and T cell activation. Ligation of CD44 has shown 
enhanced cytotoxic activity of NK cells (Galandrini et al; 1994). Over the course of 
co-cultivation, CD44 expression stayed at a relatively low level. NK cells co-
cultivated with Native K562 showed higher level of CD44 expression on Day 7, but 
it faded away by Day 14. 
 
 
Figure 25: CD44 Expression on NK cells expanded on K562 aAPCs 
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4.4 MULTI-DIMENSIONAL FLOW CYTOMETRY ANALYSIS BY SPADE 
Flow cytometry data from NK cells cultivated from five donors with IL-21 membrane 
bound K562 was concatenated, and tested to see the changes of proportion over 
time for certain phenotypes. 
There were three panels tested to accommodate multiple markers. The first panel 
was clustered with 9 markers, 3KIRs, NKp30, CD319, CD62L, 2B4, CD16, NKG2D, 
CD57, and CD117. Among the 9 markers, only 3KIRs, NKp30, CD16, and NKG2D 
were annotated since they showed clear separation for annotation. There were 
four different phenotypes defined.  
Group A represents 3KIRs-NKp30-CD16+NKG2D-. Group B represents 
3KIRs+NKp30-CD16+NKG2D+. Group C represents 3KIRs-NKp30+CD16+NKG2D+. 
Group D represents 3KIRs+NKp30+CD16+NKG2D+. 
Group A, which was dominating population on Day 0, showed its dominance on 
Day 0, but was differentiated into activated forms on Day 7 and 14. Group B and 
C were intermediates during the activation, and were well captured on Day 7. 
Group D showed highest proportion on Day 14. 
By using this SPADE analysis, SPADE figures were generated (Figure 26, Figure 
27, Figure 28) to visualize the cell differentiation over time, and also the proportion 
of each donor was plotted in a bar chart to show the difference between donors 
(Figure 29, Figure 30, Figure 31).  
Panel 2 consisted of 8 makers clustered, LFA-1, NKG2C, CD96, ILT2, TIGIT, TIM-
3, CD2, and CD57, and only LFA-1, CD96, and CD2 were annotated. 
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Group A represents LFA-1- CD96-CD2+. Group B represents LFA-1+ CD96+CD2+. 
Group C represents LFA-1+ CD96-CD2+. Group A was the dominating phenotype 
on Day 0, Group B was on Day 7, and both B and C dominated on Day 14. In this 
panel, Group B could be considered the idealistic phenotype, but it lost some of its 
expression of CD96 on Day 14, thereby it became the phenotype Group C, which 
lacks CD96 expression. The reason why CD96 loses its expression after it peaked 
on Day 7 will require further investigation. 
Panel 3 consisted of 8 markers clustered, CD164, NKG2A, CD52, CD81, 
CD45RO, CD45RA, CD44, and CD57. Four of them, NKG2A, CD81, CD45RO, 
CD45RA, were annotated. Group A represents NKG2A-CD81-CD45RO-CD45RA+. 
Group B represents NKG2A+CD81+CD45RO+CD45RA-. Group C represents 
NKG2A-CD81+CD45RO+CD45RA-.  
In this panel, it is good to have NKG2A and CD81 expressed, but CD45RA is 
expressed on naïve T cell or resting NK cells, and CD45RO is expressed on 
effector T cell or activated NK cells. Therefore, the idealistic phenotype in this 
panel should have NKG2A, CD81, and CD45RO expressed, which is presented 
as Group B. 
Group A dominated on Day 0, whereas Group B and C dominated on Day 7 and 
14. It is questionable why Group B is not maintained at a high proportion during 
the co-cultivation, which requires further investigation.
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Figure 26: Day 0, 7, and 14 (Left to Right) SPADE Analysis of donor SLR833. Panel 1. 
 
 
 
Group A B C D 
% 70.08 0.01 0.39 0.19 
Group A B C D 
% 6.53 5.80 16.41 19.36 
Group A B C D 
% 4.19 1.84 5.53 31.95 
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Figure 27: Day 0, 7, and 14 (Left to Right) SPADE Analysis of donor SLR833. Panel 2. 
 
 
Group A B C 
% 31.78 1.50 32.10 
Group A B C 
% 0.85 74.43 4.39 
Group A B C 
% 1.43 39.62 48.28 
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Figure 28: Day 0, 7, and 14 (Left to Right) SPADE Analysis of donor SLR833. Panel 3. 
Group A B C 
% 62.02 0.21 0.57 
Group A B C 
% 0.29 46.43 44.30 
Group A B C 
% 0.83 16.24 38.37 
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Figure 29: Phenotype group proportion changes over time for Panel 1. 
 
 
Figure 30: Phenotype group proportion changes over time for Panel 2. 
 
61 
 
 
Figure 31: Phenotype group proportion changes over time for Panel 3. 
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4.5 GLUCOSE AND OXYGEN CONSUMPTION PROFILE 
Glucose measurement was plotted in Figure 33 showing cumulative consumption 
of glucose. The consumption at the beginning of the culture was higher than usual 
due to the K562 cells consumed glucose until they were lysed by NK cells. At the 
beginning, the ratio between NK cell and K562 cells was approximately 1:10, 
whereas re-stimulation on Day 7 required only 1:1 ratio, which did not give 
significant impact on glucose consumption. While the number of cell reached 10 
billion compared to the initial cell population of approximately 1.6 million cells, cells 
consumed total of about 70 mmol of glucose over the 14-day cultivation. 
 
 
 
Figure 32: Cumulative cell number during glucose measurement 
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Figure 33: Cumulative glucose measurement 
 
4.6 COLLECTION OF KINETIC PARAMETERS OF NK AND K562 CULTURES 
4.6.1 NK Cells 
Cell Size 
NK cells isolated from one donors and depleted with CD3 and CD19 cells as 
described in Materials and Methods were inoculated in a T-75 flask at 0.4 x 106 
cells/mL. A 1-mL sample was collected on Day 3 of the culture, and measured the 
cell size distribution with Vi-Cell XR Analyzer. Mean diameter of NK cells was 
10.81 x 10-6 m, and standard deviation of the mean diameter was 3.46 x 10-6 m. 
The distribution diagram was shown in Figure 34. 
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Figure 34: NK Cell Diameter Distribution 
 
Specific Rate Amino Acids 
NK cells were isolated from PBMCs using magnetic bead depletion of CD3 and 
CD19 cells.  NK Cells were placed in a T-75 flask at a concentration of 0.2 x 106 
cells/mL. Initially the actual concentration of NK cells from the heterogeneous 
culture that consists of NK Cell and Monocyte are approximately 1:5; thus, making 
the approximate cell centration of NK Cells to be 0.04 x 106 cells/mL. The NK cells 
were stimulated by K562.mbIL21 Cells at a ratio of 1:10. Media was changed at 
Day 3,5,7,10, 12 respectively per descriptions in Materials and Methods. Samples 
were collected during the media change, and were analyzed by HPLC. 
Concentration of amino acids throughout the cultivation was shown in Figure 35, 
Figure 36, Figure 37, Figure 38. 
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Specific rate of amino acids consumption or production was shown in Figure 39, 
Figure 40, Figure 41, Figure 42. 
Cumulative rate of amino acids consumption or production was shown in Figure 
43, Figure 44, Figure 45. 
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Figure 35: Concentration of Essential Amino Acids Histidine, Methionine, 
Phenylalanine, Lysine 
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Figure 36: Concentration of Essential Amino Acids Valine, Isoleucine, Leucine 
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Figure 37: Concentration of Non-Essential Amino Acids Serine, Arginine, Tyrosine, 
Cysteine, Tryptophan 
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Figure 38: Concentration of Non-Essential Amino Acids Glutamate, Glycine, 
Alanine, Glutamine 
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Figure 39: Specific Rate of Essential Amino Acids Histidine, Methionine, 
Phenylalanine, Lysine 
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Figure 40: Specific Rate of Essential Amino Acids Threonine, Valine, Isoleucine, 
Leucine 
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Figure 41: Specific Rate of Non-Essential Amino Acids Glutamate, Glycine, Alanine, 
Glutamine 
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Figure 42: Specific Rate of Non-Essential Amino Acids Serine, Arginine, Tyrosine, 
Cysteine, Tryptophan 
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Figure 43: Cumulative Concentration of Essential Amino Acids Histidine, 
Methionine, Phenylalanine, Lysine, Valine, Isoleucine, Leucine 
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Figure 44: Cumulative Concentration of Non-Essential Amino Acids Serine, 
Arginine, Tyrosine, Cysteine, Tryptophan, Glutamate, Glycine, Alanine 
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Figure 45: Cumulative Concentration of Non-Essential Amino Acids Glutamine 
 
Specific Consumption Rate of Glucose and Production Rate of Lactate 
NK cells were isolated from PBMCs using magnetic beads to enrich CD56 
population. Cells were placed in 24 well plate with working volume of 1 mL. The 
media was supplemented with 50 IU/mL of IL-15. The media was replenished at a 
full volume on Day 7. Samples were taken on Day 5, 7, 12, 16 respectively, and 
were analyzed the concentration of glucose and lactate. 
Cumulative concentration of glucose consumption and lactate production were 
shown in Figure 46. 
Specific rates of glucose consumption and lactate production were shown in Figure 
47.  
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Figure 46: Cumulative Concentration of Glucose Consumption and Lactate 
Production 
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Figure 47: Specific Rate of Glucose Consumption and Lactate Production 
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Specific Consumption Rate of Oxygen 
In order to determine the effect of NK cell activation on the rate of oxygen 
consumption, pure CD56 populations were isolated from donor’s blood using CD56 
Enrichment Kit, and started cultivation in T-75 flask using B0 media. Then, the 
oxygen consumption rate was measured in three different conditions; right after 
isolation, after three days of cultivation with no feeder cells, after three days of 
cultivation with K562.mbIL21 (shown in Figure 48). The oxygen consumption rate 
was the lowest when the cells were isolated from the blood. Compared to the cells 
cultivated without feeder and with feeder cells, those cultivated with feeder cells 
showed higher consumption of oxygen that may be caused by activation. 
 
Figure 48: Specific Consumption Rate of Oxygen 
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4.6.2 K562 Cells 
Cell Size 
Native K562 cells thawed and were inoculated in a T-75 flask at 0.8 x 106 cells/mL. 
A 1-mL sample was collected on Day 3 of the culture, and measured the cell size 
distribution with Vi-Cell XR Analyzer. Mean diameter of NK cells was 15.71 x 10-6 
m, and standard deviation of the mean diameter was 4.09 x 10-6 m. The distribution 
diagram was shown in Figure 49. 
 
Figure 49: K562 Cell Diameter Distribution 
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Specific Consumption Rate of Glucose for Irradiated K562 Cells 
K562 Cells were cultivated with RPMI-1640 media with 10% Fetal Bovine Serum. 
Cells were harvested and irradiated using a x-ray irradiator at a 10,000 cGy. Cells 
were cryopreserved in a cryotubes. At the point of thaw, K562 Cells were thawed, 
and cultivated in a T-75 flask with B0 media supplemented with 10% Human 
Serum. Cells number was measured on Day 0 and 2. Supernatant samples were 
taken on Day 0 and 2, and were measured the concentration of glucose. 
Specific rate of glucose consumption at Day 1 was 7.13 x 10-10 mmol/cell/hour. 
Cell concentration and glucose concentration were shown in Figure 50, Figure 51. 
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Figure 50: Cell Concentration of Irradiated K562 
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Figure 51: Glucose Concentration of Irradiated K562 Culture 
 
 
4.7 INVESTIGATION OF MEDIA ON NK GROWTH BEHAVIOR 
Nutrient Rich Chemically Defined Media 
Blood from three donors were used. NK cells were isolated from PBMCs using 
magnetic beads for CD3 and CD19, making a heterogeneous population consists 
of NK cell and monocyte. The cells were placed in a T-75 flask at an initial 
concentration of 0.2 x 106 cells/mL. Irradiated K562.mbIL21 cells were thawed at 
an initial concentration of 0.4 x 106 cells/mL to stimulate NK cells. Media was 
replenished and NK cells were re-stimulated per the instruction in Materials and 
Methods. 
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The cells were cultivated using three different types of media. B0, CD013-22 
(obtained from BioEngine, China), and a mixture of B0 and CD013-22 at a 1:1 
ratio. 
Figure 52 and Figure 53 show the amino acids composition of B0 and B0/CD013-
22 (1:1 Mixture). 
NK cell expansion profile is shown in Figure 54. NK cells expanded with B0 media 
showed the highest proliferation. The number of fold expansion at the end of two 
weeks cultivation using B0, CD013-22, B0/CD013-22 (1:1 Mixture) was 13603, 
1041, 3616, respectively.  
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Figure 52: Essential Amino Acid Composition of B0 and B0/CD013-22 (1:1 Mixture) 
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Figure 53: Non-Essential Amino Acid Composition of B0 and B0/CD013-22 (1:1 
Mixture) 
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Figure 54: NK Cell Expansion Profile Using Media B0, CD013-22, B0/CD013-22 (1:1 
Mixture) 
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Effect of K562 Supernatant on NK Cell Growth 
In order to determine if there is effect on the molecules secreted from K562 during 
the cultivation, irradiated K562 cells were thawed in a T-75 flask at an initial 
concentration of 0.4 x 106 cells/mL. After three days of cultivation, cells were 
harvested, and the supernatant was filtered with a 0.2 µm Poly Ethylene Sulfone 
(PES) filter unit. 
NK cells were isolated from one donor’s PBMCs using magnetic bead for CD56 
enrichment. Cells were placed in a 24 well plate at an initial cell concentration of 1 
x 106 cells/mL. The supernatant was mixed with B0 media to generate three 
different kinds of conditioned medium: 0% Conditioned Media, 50% Conditioned 
Media, 100% Conditioned Media. 0% Conditioned Media contains 100% B0 media, 
and 100% Conditioned Media contains 0% B0 media. 
The growth curve of NK cells cultured with different concentration of conditioned 
media was shown in Figure 55. 
100% Conditioned Media, which is pure supernatant from K562 culture showed 
the highest proliferation compared to pure B0 media. However, the difference 
between three types of conditioned medium was not significant to determine the 
effect of the conditioned media. 
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Figure 55: Growth Curve of NK Cells Cultivated with Varying Concentrations of 
Conditioned Media 
 
4.8 COMPARISON OF GROWTH KINETICS IN VARYING SCALES 
In conjunction with large scale experiments in T-75 flasks, small scale experiments 
were performed and analyzed by Jennifer One, advised by Prof. Samira Azarin, 
Department of Biomedical Engineering, University of Minnesota 
 
NK cells were isolated from PBMCs of three donors using magnetic bead 
separation of CD56 cells. The cells were placed in 24 well plate and T-75 flask at 
an initial concentration of 0.31 x 106 cells/mL and 0.2 x 106 cells/mL, respectively. 
The cells were stimulated by irradiated K562.mbIL21 cells at a 1:1 ratio. For media 
change and re-stimulation by K562, T-75 followed the instructions in Materials and 
Methods. For 24 well plate, media was changed when the color of media changed 
from red to yellow, and the re-stimulation and dilution frequency were kept the 
same as the T-75 flask. The difference in the initial seeding density is coming from 
the difference in volume and the surface volume of the two different vessels, and 
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the number of cells per unit area was kept the same to mimic the identical culture 
conditions except the amount of media available per unit area. 
Growth curves for both T-75 flask and 24 well plate are shown in Figure 56 and 
Figure 57. 
In order to identify the effect of the difference in the amount of media and nutrient 
available per unit area, the number of fold expansion from the two difference 
vessels were compared in Figure 58. Overall expansion was comparable until Day 
12. However, major difference in expansion occurred between Day 12 and 14, 
which requires further investigation. 
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Figure 56: Growth Curve of NK Cells Cultured in 24 Well Plate with K562.mbIL21 
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Figure 57: Growth Curve of NK Cells Cultured in T-75 Flask with K562.mbIL21 
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Figure 58: Cell Expansion Comparison Between NK Cells Cultivated in 24 Well Plate 
(Solid Line) and T-75 Flask (Dotted Line) 
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4.9 EFFECT OF STIMULATION BY LIVE AND DEAD K562 
In order to determine more details on the stimulation that NK cells receive from 
K562 cells, freshly isolated NK cells by depleting CD3 and CD19 cells were 
cultivated in T-75 flask using B0 media. One flask was stimulated by live 
K562.mbIL21 cells, and another flask was stimulated by dead K562.mbIL21 cells. 
The dead K562.mbIL21 cells were prepared by changing the medium that 
contained the cells to 35% Ethanol for 5 minutes. After 5 minutes period, the cells 
were washed with PBS, and transferred into the flask with NK cells. In terms of 
growth kinetics, NK cells cultivated with live and dead K562.mbIL21 cells showed 
similar growth. The growth curve is shown in Figure 59. 
 
 
Figure 59: Growth Curve of NK Cells Cultivated with Live and Dead K562.mbIL21 
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Another experiment was conducted to determine the effect of stimulation by K562 
further. NK cells were isolated from blood by depleting CD3 and CD19 cells, and 
were cultivated in T-75 flask. There were three different conditions tested, and their 
growth curve was shown in Figure 60. The condition shown in red line started with 
the co-cultivation of NK and K562.mbIL21, and the condition shown in blue line 
started without K562.mbIL21 stimulation. On Day 3, 10% volume of red and blue 
were exchanged so that red line contains 90% activated and 10% inactivated NK 
cells, whereas blue line contains 10% activated and 90% inactivated NK cells. Note 
here that small proportion of dead K562.mbIL21 cells and their debris were part of 
the volume that were transferred into the blue. This showed that those activated 
initially (blue) could expand when 10% volume of the red was transferred. It led us 
to suspect that dead K562 and their debris may attribute to expansion. 
Green line in the figure shows a separate experiment that started initially with a co-
cultivation of NK and K562.mbIL21 cells together. On Day 3, NK cells were isolated 
from the culture by using MACS Manual Separator (Miltenyi Biotec), which makes 
NK cells to be isolated from dead K562 and their debris. Isolated NK cells were 
transferred back to the flask to continue cultivation. Four additional days of 
cultivation showed slower growth compared to the blue line that contains 10% 
activated, 90% inactivated, plus dead K562 and their debris. The result shows to 
ascertain that physical contact to NK cells for the purpose of activation is critical 
factor for activation and expansion. 
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Figure 60: Growth Curve of NK cells Cultivated Varying Conditions of Stimulation 
 
 
 
  
86 
 
5 DISCUSSION 
It is now evident that NK cells have capability to identify multiple targets using their 
activating and inhibitory receptor. Because of this characteristic, there will be a 
number of different tumors that can be treated with NK cells. Previous methods 
expanding the NK cells were limited due to lack of robust method that failed 
supplying sufficient number of cells for allogeneic therapies. 
Recent advances in identifying and producing aAPCs helped greatly expanding 
the NK cells. While NK cells were being co-cultured with aAPCs, rapid expansion 
of NK cells and upregulation of their receptors were observed. 
It is generally accepted that NK cells cultivated with cytokines are activated and 
are better to recognize and lyse the targets compared to inactivated NK cells. 
There are a number of publications discussing the effect of the cytokines in terms 
of their functionality (Caligiuri et al., 1990). This led the cytokines be a crucial part 
of NK cell expansion protocol. 
Here we described and compared NK cell expansion using different kinds of 
membrane bound cytokines on K562. IL-2 and IL-15 are still used widely to expand 
and activate the NK cells, but the usage of IL-21 is somewhat limited due to lack 
of understanding of NK cell biology. The only known fact is that IL-15 is involved 
in signaling through STAT3 pathway, whereas IL-21 is involved in STAT5 pathway 
signaling. We showed that IL-21 membrane bound NK cells were able to expand 
as long as 35 days, and as much as 100 billion-fold expansion to provide cells for 
clinical purposes. This method provides advantages compared to the others in 
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terms of using media that does not require specialized culture media, and also 
does not require removal of T cell since the cultivation starts without any T cell 
population. These will lead to lower cost to manufacture NK cells since the cost of 
media and removal of T cell have been the costliest portion of NK cell production. 
In addition to cell expansion, it is also important to highlight the upregulation of 
receptors during the co-cultivation as a result of activation of NK cells. We were 
able to identify upregulation of receptors, such as 3KIRs, NKp30, CD16, NKG2D, 
LFA-1, CD96, CD2, NKG2A, CD81, and CD45RO. Ideally, all receptors related to 
the functionality are activated when the cells are delivered to the patients, but it 
was also observed that each marker was upregulated at different time during the 
cultivation. Some were upregulated by Day 14, others were upregulated on Day 7 
and slightly lost their expression on Day 14. This led to the need for a multi-
dimensional analysis of the data. 
SPADE analysis enabled us to overcome the limitation of conventional two-
dimensional analysis. In this study, we defined and annotated the phenotype 
based on our observation from the two-dimensional analysis. However, there were 
many other cells that were clustered enough, but did not satisfy the intensity 
criterion previously defined. By using SPADE analysis, some phenotypes that were 
not able to be defined in two-dimension can be identified, and also some subtle 
population can be identified which will require further investigation. By taking a look 
at the detailed phenotypes of the nodes that were not part of any bubble, the 
criterion of phenotypes can be refined to give better analysis. 
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While it is important to focusing on NK cell expansion to provide a reliable method, 
the NK cells expanded with allogeneic feeder cells need to be purified to remove 
potential risks of infusing cancer cells into patient’s body. Although the NK cells 
could be isolated from debris and allogeneic feeder cells, it could also be costly 
and make the overall process inefficient. Therefore, it will be our future objective 
to discover how NK cells can be expanded with safer allogeneic feeder cells or 
even without any feeder cells. It will require much deeper understanding NK cell 
biology and how NK cells get stimulated and expand ex vivo while they are in 
contact with the feeder cells. 
There are more interests in cellular metabolism that it may be involved in NK cell 
responses and also expansion. Most of studies on lymphocyte metabolism are 
focusing on T cell. Detailed studies on NK cell metabolism is at a very emerging 
stage. By understanding how metabolism of NK cell changes during the activation 
and expansion may provide important hints to develop efficient methods to expand 
NK cells without feeder cells. We have measured glucose and oxygen 
consumption of NK cells that will pave a way to continue our efforts for metabolic 
flux analysis. 
  
89 
 
6 REFERENCES 
Ahn, Y. O., Kim, S., Kim, T. M., Song, E. Y., Park, M. H., & Heo, D. S. (2013). 
Irradiated and activated autologous PBMCs induce expansion of highly 
cytotoxic human NK cells in vitro. J Immunother, 36(7), 373-381. 
doi:10.1097/CJI.0b013e3182a3430f 
Apel, M., Bruning, M., Granzin, M., Essl, M., Stuth, J., Blaschke, J., . . . Huppert, 
V. (2013). Integrated Clinical Scale Manufacturing System for Cellular 
Products Derived by Magnetic Cell Separation, Centrifugation and Cell 
Culture. Chemie Ingenieur Technik, 85(1-2), 103-110. 
doi:10.1002/cite.201200175 
Bamford, R. N., Grant, A. J., Burton, J. D., Peters, C., Kurys, G., Goldman, C. K., 
. . . Waldmann, T. A. (1994). The interleukin (IL) 2 receptor beta chain is 
shared by IL-2 and a cytokine, provisionally designated IL-T, that stimulates 
T-cell proliferation and the induction of lymphokine-activated killer cells. 
Proc Natl Acad Sci U S A, 91(11), 4940-4944.  
Barkholt, L., Alici, E., Conrad, R., Sutlu, T., Gilljam, M., Stellan, B., . . . Dilber, M. 
S. (2009). Safety analysis of ex vivo-expanded NK and NK-like T cells 
administered to cancer patients: a phase I clinical study. Immunotherapy, 
1(5), 753-764. doi:10.2217/imt.09.47 
Caligiuri, M. A., Zmuidzinas, A., Manley, T. J., Levine, H., Smith, K. A., & Ritz, J. 
(1990). Functional Consequences of Interleukin-2 Receptor Expression on 
Resting Human-Lymphocytes - Identification of a Novel Natural-Killer-Cell 
Subset with High-Affinity Receptors. Journal of Experimental Medicine, 
171(5), 1509-1526. doi:DOI 10.1084/jem.171.5.1509 
Carlens, S., Gilljam, M., Chambers, B. J., Aschan, J., Guven, H., Ljunggren, H. G., 
. . . Dilber, M. S. (2001). A new method for in vitro expansion of cytotoxic 
human CD3(-)CD56(+) natural killer cells. Human Immunology, 62(10), 
1092-1098. doi:Doi 10.1016/S0198-8859(01)00313-5 
Carson, W. E., Giri, J. G., Lindemann, M. J., Linett, M. L., Ahdieh, M., Paxton, R., 
. . . Caligiuri, M. A. (1994). Interleukin (IL) 15 is a novel cytokine that 
activates human natural killer cells via components of the IL-2 receptor. J 
Exp Med, 180(4), 1395-1403.  
Couzin, J. (2002). Cancer immunotherapy. Select T cells, given space, shrink 
tumors. Science, 297(5589), 1973. doi:10.1126/science.297.5589.1973a 
Denman, C. J., Senyukov, V. V., Somanchi, S. S., Phatarpekar, P. V., Kopp, L. M., 
Johnson, J. L., . . . Lee, D. A. (2012). Membrane-bound IL-21 promotes 
sustained ex vivo proliferation of human natural killer cells. PLoS One, 7(1), 
e30264. doi:10.1371/journal.pone.0030264 
Felices, M., Lenvik, A., Chu, S., McElmurry, R., Cooley, S., Tolar, J., . . . Miller, J. 
S. (2016). Continuous IL-15 Signaling Leads to Functional Exhaustion of 
Human Natural Killer Cells through Metabolic Changes That Alters Their In 
Vivo Anti-Tumor Activity. Blood, 128(22).  
Fujisaki, H., Kakuda, H., Shimasaki, N., Imai, C., Ma, J., Lockey, T., . . . Campana, 
D. (2009). Expansion of highly cytotoxic human natural killer cells for cancer 
90 
 
cell therapy. Cancer Res, 69(9), 4010-4017. doi:10.1158/0008-5472.CAN-
08-3712 
Geller, M. A., Cooley, S., Judson, P. L., Ghebre, R., Carson, L. F., Argenta, P. A., 
. . . Miller, J. S. (2011). A phase II study of allogeneic natural killer cell 
therapy to treat patients with recurrent ovarian and breast cancer. 
Cytotherapy, 13(1), 98-107. doi:10.3109/14653249.2010.515582 
Grabstein, K. H., Eisenman, J., Shanebeck, K., Rauch, C., Srinivasan, S., Fung, 
V., . . . et al. (1994). Cloning of a T cell growth factor that interacts with the 
beta chain of the interleukin-2 receptor. Science, 264(5161), 965-968.  
Granzin, M., Wagner, J., Kohl, U., Cerwenka, A., Huppert, V., & Ullrich, E. (2017). 
Shaping of Natural Killer Cell Antitumor Activity by Ex Vivo Cultivation. Front 
Immunol, 8, 458. doi:10.3389/fimmu.2017.00458 
Huenecke, S., Zimmermann, S. Y., Kloess, S., Esser, R., Brinkmann, A., Tramsen, 
L., . . . Koehl, U. (2010). IL-2-driven regulation of NK cell receptors with 
regard to the distribution of CD16+ and CD16- subpopulations and in vivo 
influence after haploidentical NK cell infusion. J Immunother, 33(2), 200-
210. doi:10.1097/CJI.0b013e3181bb46f7 
Kim, E. K., Ahn, Y. O., Kim, S., Kim, T. M., Keam, B., & Heo, D. S. (2013). Ex vivo 
activation and expansion of natural killer cells from patients with advanced 
cancer with feeder cells from healthy volunteers. Cytotherapy, 15(2), 231-
241 e231. doi:10.1016/j.jcyt.2012.10.019 
Koepsell, S. A., Miller, J. S., & McKenna, D. H., Jr. (2013). Natural killer cells: a 
review of manufacturing and clinical utility. Transfusion, 53(2), 404-410. 
doi:10.1111/j.1537-2995.2012.03724.x 
Kotecha, N., Krutzik, P. O., & Irish, J. M. (2010). Web-based analysis and 
publication of flow cytometry experiments. Curr Protoc Cytom, Chapter 10, 
Unit10 17. doi:10.1002/0471142956.cy1017s53 
Lapteva, N., Durett, A. G., Sun, J., Rollins, L. A., Huye, L. L., Fang, J., . . . Rooney, 
C. M. (2012). Large-scale ex vivo expansion and characterization of natural 
killer cells for clinical applications. Cytotherapy, 14(9), 1131-1143. 
doi:10.3109/14653249.2012.700767 
Levine, B. L., Miskin, J., Wonnacott, K., & Keir, C. (2017). Global Manufacturing of 
CAR T Cell Therapy. Mol Ther Methods Clin Dev, 4, 92-101. 
doi:10.1016/j.omtm.2016.12.006 
Ljunggren, H. G., & Karre, K. (1990). In search of the 'missing self': MHC molecules 
and NK cell recognition. Immunol Today, 11(7), 237-244.  
McMichael, E. L., Jaime-Ramirez, A. C., Guenterberg, K. D., Luedke, E., Atwal, L. 
S., Campbell, A. R., . . . Carson, W. E. (2017). IL-21 Enhances Natural Killer 
Cell Response to Cetuximab-Coated Pancreatic Tumor Cells. Clinical 
Cancer Research, 23(2), 489-502. doi:10.1158/1078-0432.Ccr-16-0004 
Meyer-Monard, S., Passweg, J., Siegler, U., Kalberer, C., Koehl, U., Rovo, A., . . . 
Tichelli, A. (2009). Clinical-grade purification of natural killer cells in 
haploidentical hematopoietic stem cell transplantation. Transfusion, 49(2), 
362-371. doi:10.1111/j.1537-2995.2008.01969.x 
91 
 
Miller, J. F., & Sadelain, M. (2015). The journey from discoveries in fundamental 
immunology to cancer immunotherapy. Cancer Cell, 27(4), 439-449. 
doi:10.1016/j.ccell.2015.03.007 
Miller, J. S., Oelkers, S., Verfaillie, C., & McGlave, P. (1992). Role of monocytes 
in the expansion of human activated natural killer cells. Blood, 80(9), 2221-
2229.  
Parkhurst, M. R., Riley, J. P., Dudley, M. E., & Rosenberg, S. A. (2011). Adoptive 
transfer of autologous natural killer cells leads to high levels of circulating 
natural killer cells but does not mediate tumor regression. Clin Cancer Res, 
17(19), 6287-6297. doi:10.1158/1078-0432.CCR-11-1347 
Pierson, B. A., Miller, J. S., Verfaillie, C., McGlave, P. B., & Hu, W. S. (1994). 
Population dynamics of human activated natural killer cells in culture. 
Biotechnol Bioeng, 43(8), 685-692. doi:10.1002/bit.260430803 
Siegler, U., Meyer-Monard, S., Jorger, S., Stern, M., Tichelli, A., Gratwohl, A., . . . 
Kalberer, C. P. (2010). Good manufacturing practice-compliant cell sorting 
and large-scale expansion of single KIR-positive alloreactive human natural 
killer cells for multiple infusions to leukemia patients. Cytotherapy, 12(6), 
750-763. doi:10.3109/14653241003786155 
Smyth, M. J., Cretney, E., Kelly, J. M., Westwood, J. A., Street, S. E., Yagita, H., . 
. . Hayakawa, Y. (2005). Activation of NK cell cytotoxicity. Mol Immunol, 
42(4), 501-510. doi:10.1016/j.molimm.2004.07.034 
Sutlu, T., Stellan, B., Gilljam, M., Quezada, H. C., Nahi, H., Gahrton, G., & Alici, E. 
(2010). Clinical-grade, large-scale, feeder-free expansion of highly active 
human natural killer cells for adoptive immunotherapy using an automated 
bioreactor. Cytotherapy, 12(8), 1044-1055. 
doi:10.3109/14653249.2010.504770 
Vera, J. F., Brenner, L. J., Gerdemann, U., Ngo, M. C., Sili, U., Liu, H., . . . Rooney, 
C. M. (2010). Accelerated production of antigen-specific T cells for 
preclinical and clinical applications using gas-permeable rapid expansion 
cultureware (G-Rex). J Immunother, 33(3), 305-315. 
doi:10.1097/CJI.0b013e3181c0c3cb 
Vivier, E., Tomasello, E., Baratin, M., Walzer, T., & Ugolini, S. (2008). Functions 
of natural killer cells. Nat Immunol, 9(5), 503-510. doi:10.1038/ni1582 
Walzer, T., Jaeger, S., Chaix, J., & Vivier, E. (2007). Natural killer cells: from CD3(-
)NKp46(+) to post-genomics meta-analyses. Curr Opin Immunol, 19(3), 
365-372. doi:10.1016/j.coi.2007.04.004 
Yang, Y., Jacoby, E., & Fry, T. J. (2015). Challenges and opportunities of 
allogeneic donor-derived CAR T cells. Curr Opin Hematol, 22(6), 509-515. 
doi:10.1097/MOH.0000000000000181 
 
 
